Study of Targeted Medicine Versus Placebo for Chest Pain with Non-Obstructive Coronary Arteries

What this Trial Is About

Researchers are evaluating whether targeted medical therapy can improve symptoms and quality of life in patients who have angina with non-obstructive coronary arteries, compared to placebo. The study focuses on patients whose cause of chest pain has been identified through coronary function testing. This trial is in phase 2 and phase 3 and aims to better understand treatments tailored to specific chest pain causes. Participants are assigned to receive either targeted medications or placebo after randomization. The targeted therapies include amlodipine or nebivolol, or a combination, depending on the type of coronary issue diagnosed. Treatment begins with a 1 to 3 week drug titration phase where doses are increased to the highest tolerated level. After this, participants take their reached dose for an additional 4 weeks. During the study, participants will have weekly visits or telephone calls to monitor their dosing. They will complete questionnaires assessing their quality of life, treatment satisfaction, and symptoms at the start and end of the trial. Researchers will measure outcomes such as angina symptoms using the Seattle Angina Questionnaire and other health scores, as well as track any cardiac events. The total study duration for each participant is between 5 and 7 weeks depending on the titration period.

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries